Pharma's Promising Path in COPD Treatment
Source: Streetwise Reports (04/26/2024)
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.
read more >
Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju (04/22/2024)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
read more >
PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash (04/22/2024)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
read more >
Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
read more >
LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
read more >